DeVita expects a sequential Q4 treatment-volume decline, with higher RPT and a significant IKC step-up partly offsetting the impact.
DVA · Davita Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
DeVita expects a $70 million exchange headwind in 2027, while projecting positive volume growth and larger pharmaceutical cost savings; it estimates the full-year Medicare increase at 1.5% to 2%.
DaVita reported third-quarter 2026 operating income of $499 million, down from $579 million in the second quarter, while total consolidated revenues rose to $3,578 million from $3,554 million. The quarter included a $62 million goodwill and other asset impairment charge for its China business, and ancillary services posted a $19 million operating loss. Adjusted operating income was $561 million, down 3.1%.
DaVita Inc. reported $3.578 billion in revenue, $3.40 diluted earnings per share and $519 million in operating cash flow for the quarter ended September 30, 2026. It recognized a $62 million impairment charge for its China business, resulting in a $27 million net income impact.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 4, 2026TL;DR. DaVita reaffirmed full-year 2026 adjusted operating income guidance (midpoint $2.2 billion) and adjusted EPS guidance (midpoint $14.65), raised its 2026 treatment volume outlook to the top end of its prior 25–50 bps range, and plans to deploy new expanded HD (middle molecule clearance) dialyzers across its network supported by sustained mortality improvement, though revenue per treatment and commercial mix face headwinds from ACA subsidy expiration.
- + Reaffirmed full-year 2026 adjusted operating income guidance with $2.2 billion midpoint and adjusted EPS midpoint of $14.65
- + Raised 2026 total treatment volume outlook to near the top end of prior 25–50 bps guidance range
- + Plans broad deployment of expanded HD (middle molecule clearance) dialyzers supported by secured supply and MOTHER trial non-inferiority results
- + Sustained mortality improvement is driving volume growth and supporting return to at least 2% treatment volume growth by 2029
- + Q2 adjusted operating income was $579 million with EPS of $4.02 and free cash flow of $256 million
- + Phosphate binder transition cut reliance on less effective over-the-counter options like Tums by more than 50%, expanding access to clinically prepared therapies
- − Revenue per treatment declined approximately $2 sequentially due to lower commercial mix and reduced phosphate binder revenue
- − Back-half 2026 revenue per treatment growth expected to be slightly negative year-over-year
- − Year-to-date patient care costs per treatment have grown more than 3%, above the expected full-year range
- − U.S. dialysis G&A grew roughly 10% in the quarter, pressuring operating leverage
- − CMS 2027 ESRD proposed rule base rate update again tracks below industry cost trends, and final rule impact for 2027 remains uncertain
- − Fewer admits from closed Fresenius clinics cut expected volume pickup by about five basis points year-to-date
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Acquisition expenditures | $5M | three months ended June 30, 2026 | — |
| Adjusted diluted per share non-GAAP | $4.02 | Three months ended June 30, 2026 | — |
| Adjusted net income attributable to DaVita Inc. non-GAAP | $265M | three months ended June 30, 2026 | — |
| Adjusted operating income non-GAAP | $579M | Three months ended June 30, 2026 | — |
| Amount spent on share repurchases | $348M | three months ended June 30, 2026 | — |
| Annualized aggregate risk based spend | $5.8B | June 30, 2026 | — |
| Annualized medical spend for risk-based integrated care patients | $5.8B | As of June 30, 2026 | — |
| Average patient service revenue per treatment | $415.87 | three months ended June 30, 2026 | — |
| Average price paid per share repurchased | $154.95 | During the three months ended June 30, 2026 | — |
| Average treatments per normalized day | 92,649 | the three months ended June 30, 2026 filing | — |
| Average U.S. dialysis treatments per day | 92,649 | second quarter of 2026 | — |
| Consolidated EBITDA non-GAAP | $3.02B | twelve months ended June 30, 2026 | — |
| Depreciation and amortization expense per treatment | $20.26 | three months ended June 30, 2026 | — |
| Development capital expenditures | $47M | three months ended June 30, 2026 | — |
| Effective income tax rate on income attributable to DaVita Inc. non-GAAP | 25.6% | the three months ended June 30, 2026 filing | — |
| Free cash flow non-GAAP | $396M | six months ended June 30, 2026 | — |
| Free cash flow, last twelve months non-GAAP | $1.31B | twelve months ended June 30, 2026 | — |
| General and administrative expenses per treatment | $45.79 | three months ended June 30, 2026 | — |
| Maintenance capital expenditures | $123M | three months ended June 30, 2026 | — |
| Normalized non-acquired treatment growth | 0.3% | second quarter of 2026 compared to the second quarter of 2025 | — |
| Normalized treatment days | 78 | Q2 2026 | — |
| Number of treatment days | 78 | three months ended June 30, 2026 | — |
| Operating cash flow | $490M | Three months ended June 30, 2026 | — |
| Operating cash flow, last twelve months | $2.19B | twelve months ended June 30, 2026 | — |
| Operating margin | 16.3% | three months ended June 30, 2026 | — |
| Other integrated care patients | 5,700 | June 30, 2026 | — |
| Outpatient dialysis centers | 3,266 | As of June 30, 2026 | — |
| Patient care costs per treatment | $277.4 | Three months ended June 30, 2026 | — |
| Patients in risk-based integrated care arrangements | 64,900 | As of June 30, 2026 | — |
| Patients receiving dialysis services | 298,500 | As of June 30, 2026 | — |
| Per day year-over-year change | 0.6% | three months ended June 30, 2026 | — |
| Per normalized day year-over-year change | 0.6% | three months ended June 30, 2026 | — |
| Revenue per treatment | $415.87 | Three months ended June 30, 2026 | — |
| Shares repurchased | 2.2M | During the three months ended June 30, 2026 | — |
| Total debt | $10.85B | June 30, 2026 | — |
| Total number of shares purchased | 2.24M | the three months ended June 30, 2026 filing | — |
| Total U.S. dialysis treatments | 7,226,600 | second quarter of 2026 | — |
| Treatments | 7,226,600 | three months ended June 30, 2026 | — |
| Weighted average effective interest rate at end of the quarter | 5.43% | June 30, 2026 | — |
| Weighted average effective interest rate on its senior secured credit facilities | 5.76% | end of the second quarter of 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DVA
this stock
Davita Inc.
|
$10.88B | +52.3% | +6.5% | 12.8 | 8.2% |
|
HCA
HCA Healthcare, Inc.
|
$104.69B | +7.4% | +7.1% | 16.6 | 2.3% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$33.30B | +3.1% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$22.45B | +41.9% | +0.9% | 8.2 | 2.2% |
|
EHC
Encompass Health Corp
|
$13.53B | +29.9% | +10.5% | 21.5 | 3.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DVA | -3.5% | -1.3% | -12.2% | -7.7% | +52.3% |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -1.2% | +3.4% | -9.3% | -4.7% | +44.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.